---
schema_version: "secwatch.filing_event.v1"
accession: "0001110803-26-000138"
form_type: "8-K"
ticker: "ILMN"
cik: "0001110803"
company_name: "ILLUMINA, INC."
filed_at: "2026-06-23T13:08:49+00:00"
generated_at: "2026-06-23T13:10:12.872657+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Illumina appoints Eli Lilly's CSO Daniel Skovronsky to Board effective June 16, 2026

## Summary
- Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board effective June 16, 2026; Board expanded to 10 members.
- Skovronsky is Eli Lilly's Chief Scientific and Product Officer and President of Lilly Research Laboratories.
- He brings expertise in drug discovery, clinical development, and translational medicine to Illumina's genomics focus.
- Skovronsky will participate in the standard non-employee director compensation program described in April 9, 2026 proxy.
- He qualifies as an independent director under Nasdaq and SEC rules; will stand for election at 2027 annual meeting.

## SEC filing metadata
- accession: 0001110803-26-000138
- form_type: 8-K
- ticker: ILMN
- cik: 0001110803
- company_name: ILLUMINA, INC.
- filed_at: 2026-06-23T13:08:49+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000138/0001110803-26-000138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000138/ilmn-20260616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001110803-26-000138
- JSON: https://secwatch.observer/filing/0001110803-26-000138.json
- Plain text: https://secwatch.observer/filing/0001110803-26-000138.txt

## Key facts
- Executive change
  Daniel M. Skovronsky was appointed as Director at ILLUMINA, INC..
  - Action: appointed
  - Role: Director
  source text: On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000138/0001110803-26-000138-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.